Change in number of shares and votes in Aerocrine

With reference to Chapter 4 Section 9 in ”lagen (1991:980) om handel med
finansiella instrument” it’s hereby announced that through the  subscription by
a new share issue related to the company’s stock option program in Aerocrine the
number of shares and votes in Aerocrine has increased during January 2015 as
specified in the table below. (PLEASE NOTE THAT THE CHANGE IN NUMBER OF SHARES
DUE TO THE ONGOING RIGHTS SHARE ISSUE WILL BE PUBLISHED ON FEBRUARY 27TH).

                  Number of shares and votes
January 1, 2015                  155 063 162
Increase                             353 225
January 30, 2015                 155 416 387

Solna January 30, 2015

Aerocrine AB (publ.)

For further information, please contact:

Marshall Woodworth, CFO, +1 919 749 8748 or +46 709 695 219

About Aerocrine

Aerocrine AB is a medical products company focused on improved management and
care of patients with inflammatory airway diseases such as Asthma. Within this
sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO® and NIOX
VERO®, which enables fast and reliable point-of-care measurement of airway
inflammation. These products plays a critical role in more effective diagnosis,
treatment and follow-up of patients affected with inflammatory airway diseases.
Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland
and the UK. Aerocrine shares have been listed on the Stockholm Stock Exchange
since 2007 (AERO-B.ST). For more information please visit www.aerocrine.com and
www.niox.com.

+------------------------------------------------------------------------------+
|Aerocrine may be required to disclose the information provided herein pursuant|
|to the Securities Markets Act and/or the Financial Instruments Trading Act.   |
|The information was submitted for publication at 08:00 am on January 30, 2015.|
+------------------------------------------------------------------------------+